Litcius/Paper detail

High Incidence of False-Positive Results in Patients with Acute Infections Other than COVID-19 by the Liaison SARS-CoV-2 Commercial Chemiluminescent Microparticle Immunoassay for Detection of IgG Anti-SARS-CoV-2 Antibodies

Narjis Boukli, Melchior Le Mene, Aurélie Schnuriger, Nancy Stella Cuervo, Cécilia Laroche, Laurence Morand‐Joubert, Joël Gozlan

2020Journal of Clinical Microbiology21 citationsDOIOpen Access PDF

Abstract

International audience

Topics & Concepts

SeroconversionVirologySerologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CoronavirusAntibodyImmunoassayCoronavirus disease 2019 (COVID-19)VirusMedicineImmunologyViral diseasePandemicBiologyDiseaseInternal medicineInfectious disease (medical specialty)SARS-CoV-2 detection and testingSARS-CoV-2 and COVID-19 ResearchBiosensors and Analytical Detection
High Incidence of False-Positive Results in Patients with Acute Infections Other than COVID-19 by the Liaison SARS-CoV-2 Commercial Chemiluminescent Microparticle Immunoassay for Detection of IgG Anti-SARS-CoV-2 Antibodies | Litcius